PAK6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1614473	0.42	2/20
SCHEMBL1614224	0.41	2/20
SCHEMBL1611663	0.41	2/20
SCHEMBL1613241	1.00	1/20
SCHEMBL11971116	1.00	1/20
SCHEMBL15389179	1.00	1/20
SCHEMBL12714976	0.81	1/20
SCHEMBL15388680	0.77	1/20
SCHEMBL15389105	0.76	1/20
SCHEMBL15389044	0.73	1/20
SCHEMBL12001859	0.72	1/20
SCHEMBL12742679	0.72	1/20
SCHEMBL15388836	0.72	1/20
SCHEMBL15389331	0.72	1/20
SCHEMBL12490008	0.72	1/20
SCHEMBL11970925	0.70	1/20
SCHEMBL12714969	0.70	1/20
SCHEMBL15389119	0.69	1/20
SCHEMBL14838995	0.69	1/20
SCHEMBL28668520	0.69	1/20

Clinical trials — most relevant to PAK6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer	PHASE2	COMPLETED
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery	PHASE2	WITHDRAWN
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma	PHASE2	COMPLETED
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)	nan	RECRUITING
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PAK6 binder may also engage these)

Protein	Name	Similarity
Q5R8Z4	—	1.000	Q5R8Z4 →
Q3ULB5	—	1.000	Q3ULB5 →
Q8BTW9	—	0.995	Q8BTW9 →
Q63553	—	0.994	Q63553 →
PAK4	Serine/threonine-protein kinase PAK 4	0.993	landscape →
O89084	—	0.993	O89084 →
A7MBB4	—	0.992	A7MBB4 →
O70405	—	0.992	O70405 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.991	landscape →
Q8VDU5	—	0.990	Q8VDU5 →
SNRK	SNF-related serine/threonine-protein kinase	0.990	landscape →
Q641K5	—	0.990	Q641K5 →
Q8RXT4	—	0.990	Q8RXT4 →
Q9Z1J2	—	0.990	Q9Z1J2 →
P54748	—	0.990	P54748 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.989	landscape →
A3KMV1	—	0.989	A3KMV1 →
Q66HE5	—	0.989	Q66HE5 →
Q9UPV7	—	0.989	Q9UPV7 →
Q6YY75	—	0.989	Q6YY75 →
TESK2	Dual specificity testis-specific protein kinase 2	0.989	landscape →
Q2QMH1	—	0.989	Q2QMH1 →
D3ZML2	—	0.989	D3ZML2 →
Q8BZN4	—	0.989	Q8BZN4 →
Q924U5	—	0.989	Q924U5 →
Q6DBX4	—	0.988	Q6DBX4 →
Q9H329	—	0.988	Q9H329 →
Q8CIP4	—	0.988	Q8CIP4 →
Q7ZVS3	—	0.988	Q7ZVS3 →
BMP2K	BMP-2-inducible protein kinase	0.988	landscape →